The genus Blastocystis has recently attracted the attention of scientists, especially parasitologists. Similarly to the related opalines and proteromonads, Blastocystis is anaerobic and lives endobiotically in the intestine of various animals. This organism is also often found in humans, where it is associated with irritable bowel syndrome, though its pathogenic potential remains uncertain. The genus Blastocystis is remarkable for its rich genetic diversity. The taxonomy of Blastocystis is inconsistent and problematic. The strains isolated from homoiothermic vertebrates are divided into 17 subtypes, while strains from poikilotherms are either classified as separate species or are not considered in taxonomic studies at all. The aim of the study was to further examine the genetic diversity of the genus Blastocystis. We determined SSU rDNA sequences of 38 strains isolated from poikilothermic vertebrates and arthropods. The results of our phylogenetic analysis showed that Blastocystis is considerably diverse in these hosts, and we defined 21 new subtypes. The total number of known subtypes of Blastocystis has thus increased to 38. We also examined light-microscopical morphology of some strains. Most of the newly defined subtypes show identical morphology, ST20 (Blastocystis geocheloni) is an exception,...

No description available.

Background. Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatric disorders in childhood. Besides inattention and hyperactivity, impulsivity is the third core symptom leading to diverse and serious problems. However, the neuronal mechanisms underlying impulsivity in ADHD are still not fully understood. This is all the more the case when patients with the ADHD combined subtype (ADHD-C) are considered who are characterized by both symptoms of inattention and hyperactivity/impulsivity. Method. Combining high-density electroencephalography (EEG) recordings with source localization analyses, we examined what information processing stages are dysfunctional in ADHD-C (n = 20) compared with controls (n = 18). Results. Patients with ADHD-C made more impulsive errors in a Go/No-go task than healthy controls. Neurophysiologically, different subprocesses from perceptual gating to attentional selection, resource allocation and response selection processes are altered in this patient group. Perceptual gating, stimulus-driven attention selection and resource allocation processes were more pronounced in ADHD-C, are related to activation differences in parieto-occipital networks and suggest attentional filtering deficits. However, only response selection processes, associated with medial prefrontal networks, predicted impulsive errors in ADHD-C. Conclusions. Although the clinical picture of ADHD-C is complex and a multitude of processing steps are altered, only a subset of processes seems to directly modulate impulsive behaviour. The present findings improve the understanding of mechanisms underlying impulsivity in patients with ADHD-C and might help to refine treatment algorithms focusing on impulsivity.

In Anbetracht der enormen Verbesserung der HCV-Therapie durch die Entwicklung hochwirksamer und direkt wirkender Virostatika (DAA) dient diese Studie der Analyse von HCV-Koinfektionen unter den gemeldeten HIV-Neudiagnosen in Deutschland. Zunächst wurde die Eignung zweier kommerzieller HCV Ag/Ab ELISAs, dem Murex (Abbott) und dem Monolisa (Bio-Rad), zum Nachweis von HCV in getrockneten Serumspots (DSS) verglichen. Der Murex-ELISA zeigte sich sensitiver bei Antigen-positiven Plasma-HCV-Serokonversionsproben während der Monolisa eine höhere Sensitivität bei HCV-Antikörper-positiven DSS-Eluaten. Des Weiteren wurde ein Aviditätstest zur Unterscheidung von neuen und bereits länger bestehenden Infektionen bei einem Aviditätsindex Cut-off von 40% und einem Zeitraum von 364 Tagen etabliert. Von den insgesamt 6.097 untersuchten Proben der Jahre 2015-2017 waren 396 HCV-ELISA-reaktiv (6,5%). Von diesen wurden 256 (64,6%) als aktive und 140 (35,4%) als ausgeheilte Infektionen identifiziert. Ein hoher Anteil der HCV-Koinfektionen wurde bei intra-venösen Drogenkonsumenten (77,8%, n=168/216), in der Altersgruppe der 30-39 Jährigen (9%, n=179/1.978) und bei Menschen osteuropäischer Herkunft (38,3%, n=124/324) beobachtet. Im Vergleich zum Jahr 2016 hat sich der Anteil der ausgeheilten Infektionen im Jahr 2017 bei der Gesamtzahl der Patienten (p<0,01) sowie insbesondere bei Personen ausländischer (p<0,01) und osteuropäischer (p<0,05) Herkunft erhöht. Die HCV Subtypen (St)-1a, St-3a und St-1b waren mit 33,9% (n=79/233), 33,5% (n=78/233) und 23,3% (n=52/233) vorherrschend. Der Anteil der St-1a- und St-1b-Proben, deren HCV-Sequenz gegen DAAs resistent ist, war in allen untersuchten Jahren hoch (25%-42,9%). Der beobachtete Anstieg des Anteils der ausgeheilten HCV-Koinfektionen kann auf die DAA-Therapie zurückgeführt werden. Es sind jedoch weitere Anstrengungen erforderlich, damit Gruppen mit weiterhin hoher HCV-Prävalenz von dieser Behandlung profitieren. / In light of the major shift in HCV therapy resulting from the availability of highly potent direct acting antivirals (DAA), this study performed a surveillance of HCV coinfections among reported HIV new diagnoses in Germany. First the suitability of two HCV Ag/Ab ELISAs, Murex (Abbott) and Monolisa (Bio-Rad) for dried serum spots (DSS) was compared. The Murex was more sensitive in antigen positive plasma HCV seroconversion samples while the Monolisa showed a higher sensitivity in HCV antibody positive DSS eluates. Furthermore, an avidity test was established to distinguish between new and already longer existing infections at an avidity index cut-off of 40% and a period of 364 days. Of the total of 6,097 samples examined for the years 2015-2017, 396 were HCV ELISA reactive (6.5%). Of these, 256 (64.6%) were identified as active and 140 (35.4%) as resolved infections. A high proportion of HCV coinfections were observed in intravenous drug users (77.8%, n=168/216), in the age group 30-39 years (9%, n=179/1,978) and in people of Eastern European origin (38.3%, n=124/324). Compared to 2016, the proportion of resolved infections in 2017 has increased in the total number of patients (p<0.01) and especially in people of foreign (p<0.01) and Eastern European (p<0.05) origin. HCV subtypes (St)-1a, St-3a, and St-1b were predominant with 33.9% (n=79/233), 33.5% (n=78/233) and 23.3% (n=52/233), respectively. The proportion of St-1a and St-1b samples whose HCV sequence has resistance to DAAs was high in all diagnoses years (25%-42.9%). The observed increase in the proportion of resolved HCV coinfections can be attributed to DAA therapy. However, further efforts are needed to ensure that groups with continued high HCV prevalence benefit from this treatment.

No description available.